CORONA
18.3.2021 01:03:12 CET | Business Wire | Press release
Corona today launches a new, circular form of packaging for six-packs as part of its long-standing dedication to protecting the environment – harnessing surplus barley straw to create a truly sustainable paper packaging solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005586/en/
Corona, which has a deep connection with the natural world, is the first global brand to leverage technology and processes three years in development by AB InBev’s Global Innovation and Technology Center (GITEC). This ground-breaking technology reimagines how to use barley, giving the essential beer ingredient new life as a sustainable packaging solution.
Barley seed will continue to make the beer that consumers know and love. But barley straw, a leftover from farmers' harvests, will now be used through a unique pulping process built to handle its relative fragility.
Combined with 100% recycled wood fibers, this process creates a paper board to produce new packaging that is as strong and durable as a regular six-pack, but better for the planet – able to carry six cold beer bottles from the store fridge to the beach, but using far fewer resources along the way.
Turning barley straw into paper fiber uses 90% less water in its production than the traditional virgin wood process, along with less energy and fewer harsh chemicals. Using leftover barley straw is also far more productive than the equivalent area of woodland, and Corona sees this as one path forward to eliminate the need for virgin trees and raw material from their supply chain in the future.
Upon completion of the successful pilot, AB InBev, Corona’s parent company and the leading brewer in the world, will review rolling out the technology to other brands thereby increasing the potential positive environmental impact and the ability to influence the whole beverage industry.
Felipe Ambra, Global Vice President of Marketing, Corona, said: “Corona is a brand born at the beach. We’re deeply connected with nature and appreciate all that it has to offer, so we want to continue to do our part to protect it. Our deep reverence for nature is what inspires our vision to become a sustainability leader in the CPG industry, because we want everyone to be able to keep enjoying paradise.
Starting with our own packaging, we assessed where we could make changes within our production and supply chains to make a real difference. We are proud to announce this first step in reinventing the future of packaging for our industry.”
Keenan Thompson, Director of Packaging Innovation at AB InBev, said: “We’re excited to finally launch this new packaging innovation we’ve been developing over the past three years. At AB InBev we are continually pushing boundaries by developing scalable solutions. Today is a proud moment for us, not only are we providing an opportunity for farmers but we’re also delivering a more mindful solution to the consumer.”
The new packaging will launch today with an initial 10,000 six-packs rolling out as a pilot in Colombia in March, followed by Argentina later in 2021 as Corona looks to scale the new solution globally.
*****
Notes to Editor:
* when compared to traditional virgin wood pulping processes
Equivalent area of woodland is calculated with data from Washington State.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005586/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
